Objectives: In adults, primary sclerosing cholangitis (PSC), a cholestatic liver disease characterized by inflammation/fibrosis of intra/extrahepatic bile ducts, associates with a milder form of inflammatory bowel disease (IBD), particularly ulcerative colitis (UC). The pediatric PSC-IBD phenotype is less well characterized. Methods: We performed a retrospective, single-center study examining patients with PSC-IBD at Texas Children's Hospital between 2000 and 2015. IBD-phenotype (Modified Montreal Classification), medications, laboratory values, endoscopic records, and IBD-based hospital admissions were collected. PSC-UC phenotype was compared to UC, non-PSC patients (n ¼ 95) from Texas Children's Hospital. Elevated gamma-glutamyl transpeptidase levels were compared to calprotectin levels and IBD-flare activity, that is, gastrointestinal symptoms resulting in office/emergency department visits or hospital admission. Results: Of 39 patients with PSC-IBD, 34 (87.2%) had UC (PSC-UC) and 5 (12.8%) had Crohn disease. Pancolitis was more common in PSC-UC than UC, non-PSC (96.3%, 64%, P ¼ 0.0009). Patients with PSC-UC required less treatment with steroids (76.5%, 91.6%, P ¼ 0.0326) or infliximab (8.8%, 37.9%, P ¼ 0.0011), and fewer had at least 1 IBD-related hospital admission (32.4%, 63.2%, P ¼ 0.0025) than UC, non-PSC. Progression to colectomy was significantly less (5.8%, 24.2%, P ¼ 0.0223) in PSC-UC. Median diagnosis-to-colectomy time tended to be longer in PSC-UC (6.37, 2.5 years, P ¼ 0.0792). In 2 smaller subsets, gamma-glutamyl transpeptidase did not correlate with calprotectin in PSC-UC (n ¼ 11, P ¼ 0.7922) and less strongly associated with IBD-flares in PSC-UC than UC, non-PSC (n ¼ 33, n ¼ 67; 15.2%, 41.8%, P ¼ 0.0120). Conclusions: Pediatric PSC appears to associate with milder pancolitic-UC. PSC and IBD activity do not appear to correlate. Our findings may provide useful information toward etiology and management of pediatric PSC-IBD.
P rimary sclerosing cholangitis (PSC) is a rare progressive cholestatic liver disease characterized by inflammation and fibrosis of intra-and/or extrahepatic bile ducts. Clinical manifestations of PSC are typically secondary to cholestasis and progressive fibrosis, including jaundice, hepatomegaly, splenomegaly, recurrent cholangitis, and intractable pruritus (1) (2) (3) . Little is known about the etiology and treatment of PSC, with no current therapies conclusively proven to alter the natural history of the disease (2) .
PSC is strongly associated with inflammatory bowel diseases (IBDs) (2) . In adult patients, studies indicate that the most common PSC-IBD phenotype is a clinically milder, but more extensive (larger portion of the colonic mucosa affected) form of ulcerative colitis (UC) (2, 4) . Adult-based population studies found 46% to 98% codiagnoses of IBD in patients with PSC, with UC as the most common form (48%-90% of PSC-IBD) (2, 4, 5) . Based on various
What Is Known
Primary sclerosing cholangitis is a rare cholestatic disease with inflammation/fibrosis of intra-and/or extrahepatic bile ducts. In adults, primary sclerosing cholangitis strongly associates with a clinically extensive but milder inflammatory bowel disease phenotype. There is little evidence of etiology/treatment of primary sclerosing cholangitis in either adults or children.
What Is New
Similar to adults, pediatric primary sclerosing cholangitis appears to associate with a milder pancoliticulcerative colitis phenotype. Pediatric patients with primary sclerosing cholangitis -ulcerative colitis appear to require less medical therapy and have lower colectomy rates for inflammatory bowel disease control than pediatric patients with ulcerative colitis. In a smaller cohort subset with history of gammaglutamyl transpeptidase laboratory collection, elevated gamma-glutamyl transpeptidase levels do not correlate with elevated calprotectin or ulcerative colitis-flare activity in pediatric primary sclerosing cholangitis -ulcerative colitis.
adult reports, it appears as though the majority of the PSC-IBD population is white males. It should be noted, however, that these reviews or reports were predominantly based in North America and Northern Europe (5, 6) . Rectal sparing in PSC-IBD has wide variance in adult population studies, with incidence ranging from 5.6% to 66.4% in one large systematic review (5) . In addition, patients with PSC-IBD have an increased risk of cholangiocarcinoma (CCA), with 1 study indicating a 14% risk of developing CCA within 10 years in patients codiagnosed with IBD (vs 2% in patients without IBD, P ¼ 0.008) (7) . Colorectal cancer has also been associated with PSC-IBD, as a large-scale meta-analysis concluded higher risk of colorectal cancer when compared to non-IBD PSC patients (odds ratio 4.79, 95% confidence interval 3.58-6.41, P ¼ 0.04) (8) .
Few studies have focused on the pediatric PSC population, with even less examining the PSC-IBD phenotype. One retrospective review reported a pediatric PSC incidence of 0.23 per 100,000 patients, significant for shorter life expectancy than the age and sex-matched general population (1) . A recent study by Lascurain et al (9) compared a multicenter cohort of pediatric patients with PSC-IBD (n ¼ 37) to pediatric patients with IBD without PSC (n ¼ 137). Although prevalence of pancolitis was higher in their PSC-IBD population (89.7% vs 72.4%, P ¼ 0.051), other clinical characteristics-rectal sparing, disease severity scores, IBD-related admissions, and colonic surgery rates-showed no statistical difference when the groups were compared. The goal of our single center-based work was to provide added information about the pediatric IBD phenotype associated with PSC. Previous studies have shown that interobserver variation of IBD care exists between different tertiary adult and pediatric centers. This includes differences in diagnostic pathological accuracy and variations in therapeutic treatment plans (ie, significant variation in use of antibiotics, immunomodulators, steroids, aminosalicylates, and infliximab) (10) (11) (12) . Our single-center approach attempted to provide means to overcome center-based practice bias in regards to IBD care.
MATERIALS AND METHODS
We performed a retrospective, single-center study to examine PSC-IBD in patients seen at Texas Children's Hospital (TCH) between January 2000 and June 2015. Located in the diverse metropolitan area of Houston, TX, TCH offered a geographic and ethnically unique populace of pediatric patients diagnosed with this rare condition from a single tertiary center. PSC was defined by a combination of clinical, biochemical, and cholangiographic standards. This included a cholestatic biochemical profile (ie, elevated transaminase levels, elevated gamma-glutamyl transpeptidase [GGT]) with at least one radiological or histological finding. Cutoff levels for elevated aspartate transaminase (AST), alanine transaminase (ALT), and GGT were based on standardized laboratory reference values, corrected for age and sex. Radiologic findings were based on cholangiography (ie, magnetic resonance cholangiography, endoscopic retrograde cholangiography, percutaneous transhepatic cholangiography) consistent with characteristic bile duct changes (ie, multifocal strictures, segmental dilatations) (4). Histological records of liver biopsies were reviewed for each patient, noting findings by expert pathologists compatible with PSC (ie, bile duct damage, ''onion-skin'' fibrosis). These findings were important for defining the small-duct PSC variant, in which typical cholestatic and histologic features of PSC are present without bile duct findings on cholangiogram (4). Patient records were reviewed for other etiologies of liver disease and were excluded if pathology reports were consistent with alternative cholestatic diagnoses (ie, biliary atresia). None of the patients included in our study had history of viral hepatitis, although only 50% (n ¼ 17) had records of serologic screening. Those with incomplete or poorly documented records were also removed. Thirteen (n ¼ 13) patients in our cohort had codiagnosis of autoimmune hepatitis and were not excluded from the study.
All patients with IBD had clinical diagnoses based on established records of clinical features (ie, hematochezia, chronic watery diarrhea, severe abdominal pain) in combination with characteristic endoscopic (ie, inflammation, ulceration, friability, fissures, fat wrapping, etc), imaging and histopathologic findings (ie, inflammation, crypt architecture irregularity, crypt abscesses, granulomas, etc).
Patients were either diagnosed before evaluation, or were newly diagnosed with PSC at TCH. The data extracted from patient charts included age at diagnosis of PSC and IBD, IBD phenotype/ severity (Modified Montreal Classification) (13) , medication history, IBD-based hospital admissions (admission secondary to abdominal pain, diarrhea, weight loss, and/or fevers), disease-focused laboratory values (ie, AST, ALT, GGT, calprotectin), presence or absence of rectal sparing upon IBD diagnosis, and colectomy status. PSC-IBD (with particular focus of PSC patients with UC) was compared to a cohort of patients with UC without PSC (UC, non-PSC) from the same center. The 2 groups were matched by sex, ethnic distribution, and by median age of UC diagnosis (11.72 vs 12.0 years, P ¼ 0.65). Full breakdown of age, sex, and ethnicity can be found in Table 1 for the groups studied. IBD flares were based on patient chart review, defined as clinical symptoms of IBD (ie, loose stools, hematochezia, weight loss, abdominal pain, tenesmus, stool occult blood) leading to an office visit, emergency department visit, or hospital admission. Patients with IBD flares were reviewed for concomitant Clostridium difficile infection. One patient (n ¼ 1) in the control group had documented positive C difficile toxin during their UC flare. This patient was not removed from the UC flare subset and was treated for both the UC symptoms and C difficile colitis during their hospital admission. Of the remaining subset of patients with documented IBD flares, none were positive for C difficile toxin.
PSC-IBD subgroups were defined by histologic and endoscopic results, in combination with review of clinical records. Modified Montreal Classification (13) was used in determination of colitis in patients with UC, ranked from E1 (ulcerative proctitis) to E4 (pancolitis; a category delineated in the pediatric population). Modified Montreal Classification was also used for our 5 patients with Crohn disease (CD), which ranked from L1 (distal 1/3 ileum AE limited cecal disease) to L4b (upper disease distal to ligament of Treitz and proximal to distal 1/3 ileum) (13) . Rectal sparing was based on endoscopic findings (ie, lack of gross inflammatory findings of the rectum). It should be noted that 45 of the 95 control patients had either incomplete or missing colonoscopic records and were not included in this subset analysis of the degree of colitis based on Modified Montreal Classification. Otherwise, all 95 patients in the control were analyzed for treatment history and frequency of hospital admissions.
For our study, we associated elevated GGT levels as a marker of PSC disease activity and elevated calprotectin as a marker of UC disease activity. All calprotectin levels were extracted from the PSC-UC cohort. GGT levels drawn within 14 days of these calprotectin labs were paired and analyzed for correlation. Furthermore, the highest recorded GGT value (GGT max ) was extracted from each of the patients with PSC-UC (n ¼ 33, 1 patient was removed from this specific subanalysis due to lack of GGT recorded). Within 14 days of GGT max , medical records were investigated for evidence of IBD flare activity. Positive flare activity was defined as active gastrointestinal symptoms and physical examination findings (ie, loose stools, hematochezia, abdominal pain, tenesmus, stool occult blood) leading to urgent office visit, emergency department visit, or hospital admission. used to analyze mean time from UC diagnosis to colectomy and mean time between diagnosis of UC and PSC. All tests were 2-tailed, and statistical significance was set at P < 0.05. Colectomy data were analyzed using uncensored KaplanMeier probability estimators with subsequent log rank analysis. Kaplan-Meier analysis was performed with RStudio version 0.99.491 with the aid of ''survival'' version 2.38-1.
RESULTS

Patient Population
Our initial search of TCH electronic medical records resulted 62 patients with possible diagnosis of PSC. After removal of patients for insufficient records (ie, lack of and/or poor documentation, misdiagnosis), a total of 52 patients identified with PSC were included. Thirty-nine (75%) had a codiagnosis of IBD. Thirty-four (87.2%) of the patients with IBD had UC (PSC-UC) and 5 (12.8%) had CD.
Primary Sclerosing Cholangitis-Ulcerative Colitis
Secondary to the overwhelming majority of UC amongst the patients with PSC-IBD, we further focused on PSC-UC and compared those to a cohort of patients with UC without PSC (UC, non-PSC, n ¼ 95). PSC was diagnosed before (ie, >6 months before), simultaneously (ie, within 6 months), or after the diagnosis (ie, >6 months after) of UC in 5.9%, 64.7%, and 29.4% of patients, respectively. Average time between diagnoses was 44.8 months when UC was diagnosed first and 15.0 months when PSC was diagnosed first (P ¼ 0.14). All 34 patients with PSC-UC had history of ursodiol therapy aimed at treatment of PSC.
Clinical Outcomes in Primary Sclerosing Cholangitis-Ulcerative Colitis
Among the patients who had a full colonoscopic evaluation (27 PSC-UC, 50 UC, non-PSC), pancolitis was more common in PSC-UC than in UC, non-PSC (96.3% vs 64%, P ¼ 0.0009). There was a trend for more rectal sparing at diagnosis in PSC-UC, but this difference was not statistically significant (10.7% vs 2.2%, P ¼ 0.0861). Patients with PSC-UC were significantly less commonly treated with steroids (ie, prednisone, prednisolone) than UC, non-PSC patients (76.5% vs 91.6%, P ¼ 0.0326). Patients with PSC-UC were also significantly less commonly treated with infliximab than UC, non-PSC patients (8.8% vs 37.9%, P ¼ 0.0011). Significantly fewer patients with PSC-UC had at least 1 IBD-related hospital admission than UC, non-PSC patients (32.4% vs 63.2%; P ¼ 0.0025). Disease progression to colectomy was also significantly less common, with only 2 of 34 (5.8%) patients with PSC-UC eventually requiring surgery. In comparison, nearly a quarter (24.2%) of the 95 UC, non-PSC patients followed at TCH had eventual colectomy within 10 years from diagnosis ( Table 1 , Fig. 1 ). Median time from diagnosis of UC to colectomy tended to be longer in PSC-UC (6.37 vs 2.5 years, P ¼ 0.0739) as well.
Primary Sclerosing Cholangitis-Crohn Disease
Of the 5 patients with CD, 1 patient was classified as L2 (colonic) and 2 patients were classified as L3 (ileocolonic). The 2 remaining patients did not have complete colonoscopies adequate for classification. Therefore, all patients with CD with complete endoscopic evaluation had colonic involvement. Within the CD subcohort (n ¼ 5), PSC was diagnosed either concomitantly (ie, within 6 months) or after the diagnosis (ie, >6 months after) of CD in 40% and 60% of patients, respectively.
Disease Activity Correlation: Calprotectin and Gamma-Glutamyl Transpeptidase
Given the strong historical evidence for association between PSC and UC, we extracted clinical markers of both diseases for analysis of correlation. Of the PSC-UC cohort (n ¼ 34), 11 patients had at least 1 calprotectin level collected, with a total of 15 calprotectin levels overall. In these patients, 14 individual GGT levels collected within 2 weeks of these calprotectin labs were extracted for paired comparison (excluding 1 patient without history of GGT). Average levels of calprotectin and GGT were 433.00 mg/g and 157.64 U/L, respectively. Based on analysis of calprotectin/GGT pairs in this smaller PSC-UC subset by 2-tailed Pearson test (r ¼ 0.0775, P ¼ 0.7922), PSC activity (GGT) did not correlate with or predict UC activity (calprotectin).
Disease Activity Correlation: Ulcerative Colitis Flares and Gamma-Glutamyl Transpeptidase
We further explored possible correlation between UC and PSC disease activities by analyzing presence of IBD flares during episodes of elevated GGT (GGT max ). Thirty-three of 34 patients with PSC-UC and 67 of 95 UC, non-PSC patients had a history of at least 1 GGT laboratory test results collected. Average levels of GGT max were 481.23 and 43.88 U/L in PSC-UC and UC, non-PSC patients, respectively. Average levels of GGT max in patients with associated IBD flare were 353.00 and 58.60 U/L in PSC-UC and UC, non-PSC patients, respectively. Average levels of GGT max in patients without associated IBD flare were 520.86 and 33.30 U/L in PSC-UC and UC, non-PSC patients, respectively. Within 14 days of GGT max collection, 5 of 33 (15.2%) patients with PSC-UC had a recorded IBD flare. In comparison, within 14 days of GGT max collection, 28 of 67 (41.8%) UC, non-PSC patients had a recorded IBD flare. Therefore, patients with PSC-UC in our cohort were less likely to have an IBD flare in the setting of high GGT levels (GGT max ) when compared to the smaller subset of UC, non-PSC patients with history of collected GGT (15.2% vs 41.8%, P ¼ 0.0120; Table 2 ).
Caucasian Versus Non-Caucasian Patients With Primary Sclerosing Cholangitis-Inflammatory Bowel Disease
Upon review of recent literature, we were unable to find specific comparison of clinical outcomes in pediatric PSC-IBD between ethnic groups. Among the 34 PSC-UC patients, 20 were self-reported in medical records as Caucasian. Of the remaining 14, 6 and 5 were reported as Black and Hispanic, respectively. Three patients without ethnic classification were removed from this specific subgroup comparison. Each group had high rates of pancolitis, with E4 Modified Montreal Classification found in 92.8% and 100% of Caucasian and non-Caucasian patients, respectively (P ¼ 1.000). Both patients (n ¼ 2) requiring eventual colectomy were Caucasian, but this finding was not statistically significant (P ¼ 0.527). No significant differences were found between therapeutic treatments, including history of use of infliximab, azathioprine, or 6-mercaptopurine (6-MP) (P ¼ 0.2814, P ¼ 0.2814, P ¼ 1.000), respectively. There was, however, significantly less steroid use (ie, prednisone, prednisolone) amongst Caucasian patients with PSC-UC when compared with non-Caucasian patients with PSC-UC (35% vs 90.9%, P ¼ 0.0068). There was no significant difference between rates of having at least 1 IBD-related hospital admission between Caucasian and non-Caucasian patients with PSC-UC (20% vs 27.2%, P ¼ 0.675).
DISCUSSION
This is the largest single-center pediatric study of PSC-IBD to date. Our results indicate that a clinically less severe UC phenotype is the most common form of IBD associated with PSC in pediatric patients. Similar to our findings in children, PSC-IBD in adults has been repeatedly observed to be a clinically less severe form of UC (2, (4) (5) (6) . Of the recent reports on pediatric specific PSC-IBD, few were found to include specific comparisons between PSC-IBD and non-PSC-IBD. The previously mentioned study by Lascurain et al demonstrated a close to significant difference in pancolitis rates (89.7%, 72.4%, P ¼ 0.051) between PSC-IBD and non-PSC-IBD patients. Other outcomes in the present study, including incidence of IBD-related hospital admissions (0.19, 0.25, P ¼ 0.111), follow-up Mayo/PGA severity scores (1.7, 1.7, P ¼ 0.708; 1.0, 1.3, P ¼ 0.141), and 5-year colectomy rates (16.4%, 24.7%, P ¼ 0.27), were not significantly different between PSC-IBD and non-PSC-IBD (9). This latter study was multicenter, which may have introduced bias by different centerbased practice methods in regards to IBD care, as significant variation in the diagnostic accuracy between clinical care practices for IBD has been well described in the literature (10) (11) (12) . Although the single-center approach of our study does not remove diagnostic or therapeutic variation between our own institution's pathologists and gastroenterologists, it does allow for elimination of variable practice standards that have been demonstrated to exist between separate institutions (10) (11) (12) . We argue that in respect to IBD, the relatively consistent clinical practice within a single academic center (secondary to formal IBD case conferences encouraging similar diagnostic and therapeutic approaches) can provide advantage over multicenter-based studies, especially if those significantly depend on IBD subcategorization (ie, differential diagnosis between UC and CD, and subclassification of UC) as is the case in our study.
In a pediatric single-center study by Ordonez et al (14) , pancolitis (Modified Montreal Classification) (13) was found in 18 of 28 patients with UC and concomitant PSC, versus 8 of 27 patients with only UC (P ¼ 0.0006). The authors also observed that evolution of the colitis was less aggressive in colitis associated with autoimmune disease (CAI) than in classic UC (CUC). Another smaller retrospective study, which found 100% pancolitis among 13 patients with PSC-IBD, made no comparisons to a non-PSC-IBD group as control (15) . On the contrary, a recent single-center pediatric article described a clinically similar course of colitis in 22 patients with CAI compared with 45 CUC (16) . As comparison, our work examined 50% more patients: 34 ''CAI'' (more precisely: PSC-UC) and 95 ''CUC'' (more precisely: UC, non-PSC). These numbers are comparable to prior multicenter pediatric cohorts and carry the potential benefit to overcome center-based bias. Consistent with the adult studies, our findings revealed a relatively milder form of pancolitic UC in pediatric patients with codiagnosis of PSC when compared to UC, non-PSC patients. Of note, all completely evaluated patients with PSC-CD within our cohort had colonic involvement indicating a possible unique association between the large intestine and PSC.
A majority of our cohort had less than a 6-month span between diagnoses of UC and PSC (n ¼ 22). Of the 10 patients diagnosed initially with UC (ie, >6 months between diagnoses), there was 44.8-month average lag period before diagnosis of PSC. These patients were found to have elevated liver enzymes (ie, elevated AST, ALT, alkaline phosphatase, etc) leading to subsequent investigation and diagnosis of PSC. On the contrary, there was only a 15-month lag period in the 2 patients initially diagnosed with PSC with subsequent UC diagnosis (ie, >6 months between diagnoses). These findings are consistent with higher prevalence of UC in patients with a primary diagnosis of PSC (70%-80%) compared with lower prevalence of PSC in patients with a primary diagnosis of UC (2%-7.5%) based on a study by Loftus et al (17) . These findings, including the prevalence of UC within our study's PSC population (34 of 52 patients with PSC) suggests need for IBD surveillance in all children diagnosed with PSC.
Within our cohort, there was a trend toward rectal sparing in PSC-UC when compared to our UC, non-PSC group. This finding is consistent with both adult and pediatric literature, as the characteristic of rectal sparing in PSC-UC is suggestive of distinct disease in contrast to ''classic'' standalone UC (18, 19) . Notably, there were no findings of adenocarcinoma or CCA in our pediatric cohort.
Historically, oral glucocorticoids have been a mainstay in treatment of UC with severe exacerbations. In our study, rates of steroid use (ie, prednisone, prednisolone) in patients with PSC-UC were lower than UC, non-PSC patients, which is consistent with the already emphasized, more quiescent form of PSC-UC. It should also be noted that Caucasian patients in our study had a lower rate of steroid use when compared to non-Caucasian patients with PSC-UC. Although this finding was statistically significant, it is hard to decipher specific reasons for such a medication trend, though one may consider ethnicity-related differences in therapeutic responses. Infliximab, an anti-TNF agent, has been used in treatment against refractory IBD since its approval for use in the United States in 1998 (20) , although approval of use of infliximab in pediatric CD and UC was not until 2006 and 2011, respectively. In a meta-analysis of the efficacy of biological therapies in IBD, results reported superior remission induction rates in infliximab versus placebo in moderateto-severely active UC (20) . In our study, rates of infliximab use in patients with PSC-UC was significantly lower than UC, non-PSC. Again, this likely reflects the clinically milder phenotype of PSC-UC, because infliximab has typically been reserved for steroid and/ or thiopurine refractory cases of UC in our practice, similar to other groups (21, 22) .
Although there was no significant difference in treatment rates of patients in either PSC-UC or UC, non-PSC with thiopurines, there was a predilection of using azathioprine for PSC-UC, while UC, non-PSC was treated more often with 6-MP. Based on our own observations, this pattern may represent clinical preference amongst our group's gastroenterologists (ie, hepatologists favoring azathioprine over 6-MP).
In cases of severe refractory UC poorly responsive to medical therapies, eventual surgical colectomy is usually pursued. In our study, there was a significantly lower rate of colectomy in PSC-UC compared to UC, non-PSC. This finding further emphasizes that a clinically less severe phenotype of UC is associated with PSC in pediatric patients.
Given the historical association between PSC and UC, our study made attempts to find markers of correlation between both diseases. Fecal calprotectin, a stable protein produced within neutrophils, has commonly been used as a simple noninvasive marker of IBD activity in both adults and children (23) . Over the past 15 years, multiple studies, including 2 large meta-analyses by Henderson et al and Holtman et al (24, 25) , have demonstrated the high sensitivity of fecal calprotectin in the setting of pediatric IBD activity. GGT is an enzyme found within multiple organs, but is frequently used as a marker of disease activity in the biliary system (26) . A recent pediatric study concluded that abnormal liver enzymes, including GGT, were commonly found in pediatric IBD with associated PSC and that elevated GGT levels (>252 U/L) were highly specific for PSC in pediatric patients with IBD (specificity 99%, sensitivity 71%, AUC ¼ 0.96) (27) . In our study, we used GGT and calprotectin as noninvasive biomarkers of PSC and UC activity, respectively. When comparing calprotectin levels in our PSC-UC population to paired GGT levels drawn within 14 days of each another, there was no significant correlation between these disease activity markers. Furthermore, we also compared the highest GGT value from each patient to documentation of IBD flare activity within 2 weeks of the elevated laboratory value. There was no significant correlation between elevated GGT in prediction of IBD flares leading to office visits, emergency department visits or hospital admissions. It should be noted, however, that the population analyzed is smaller than the total cohort, with only 67 of 95 patients in the control group with history of GGT laboratory values. Although previous studies have concluded specificity of elevated liver enzymes for diagnosis of PSC in the setting of IBD, our study is the first to examine whether IBD activity may correlate with PSC activity or if the 2 disorders follow an independent course within patients with PSC-UC. Based on noninvasive biomarkers (ie, GGT, calprotectin), our findings appear to support the latter result, but with the inherent limitation of our calculations secondary to small sample size for this analysis.
Future directions include prospective studies following clinical management and outcomes of pediatric patients with PSC-UC as they transition to adulthood. Other considerations include implementation of screening protocols for pediatric patients in our institution with UC for evaluation of PSC. This is especially important as approximately 30% of our PSC-UC population had more than a 6-month gap between the initial diagnosis of UC and the diagnosis of PSC.
Limitations of our data include a small sample size compared to adult cohorts, smaller cohort size in subanalysis of GGT/calprotectin/IBD-based hospital admissions, incomplete or missing colonoscopy records among nearly half of the control patient group, and the retrospective nature of the analysis. The sample size in our single center, however, is comparable to other high-impact observations from multicenter retrospective analyses in the pediatric PSC population.
In summary, our work suggests that pediatric PSC has a significant association with a milder form of pancolitic UC when compared with UC, non-PSC. This observation implicates the importance of right-sided (ie, cecum and ascending colitis) UCrelated colon pathology in the etiology of PSC. Furthermore, PSC and UC activity appears to run an independent course amongst pediatric patients with PSC-UC, with the limitation of a small cohort of patients studied. These findings warrant further larger scale and prospective studies, and are likely to provide useful information toward the etiology, management, and possible future treatment of pediatric PSC and related IBD.
